Optimal Surgical Timing in KIT Exon 11-Mutant GIST: Insights from Radiographic and Pathology-Integrated Responses After Neoadjuvant Imatinib
Posted inGeneral Surgery news Oncology

Optimal Surgical Timing in KIT Exon 11-Mutant GIST: Insights from Radiographic and Pathology-Integrated Responses After Neoadjuvant Imatinib

This study compares radiographic versus pathology-integrated response metrics to identify optimal surgical timing after neoadjuvant imatinib treatment in KIT exon 11-mutant gastrointestinal stromal tumors (GIST). Pathology measures indicate a later window of near-maximal treatment effect than radiographic analysis.
Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up
Posted innews OB/GYN & Women’s Health Oncology

Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up

A 2-year follow-up of the ENGOT-OV60/GOG-3052/RAMP 201 trial confirms that the combination of avutometinib and defactinib offers sustained benefit and manageable safety in recurrent low-grade serous ovarian cancer, particularly in patients with KRAS mutations.
Precision Microbiome Therapeutics: Faecalibacterium prausnitzii EXL01 for Prevention of Multiple-Recurrent Clostridioides difficile Infection
Posted inClinical Updates news

Precision Microbiome Therapeutics: Faecalibacterium prausnitzii EXL01 for Prevention of Multiple-Recurrent Clostridioides difficile Infection

Faecalibacterium prausnitzii EXL01, a single commensal bacterial strain, shows promise in preventing multiple-recurrent CDI by restoring key microbiome functions, including bile acid metabolism and butyrate production, with safety and efficacy comparable to fecal microbiota transplantation.
Maternal and Neonatal Outcomes Associated with Polyendocrine Metabolic Ovarian Syndrome During Pregnancy: Insights from a Nested Prospective Cohort Study
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health

Maternal and Neonatal Outcomes Associated with Polyendocrine Metabolic Ovarian Syndrome During Pregnancy: Insights from a Nested Prospective Cohort Study

This study reveals that polyendocrine metabolic ovarian syndrome (PMOS) during pregnancy increases risks of early gestational diabetes and adverse neonatal outcomes, underscoring the need for timely identification and management to improve maternal-fetal health.